来源：oncologystat
分享：阳光明媚
肺癌
Non–Small-Cell Lung Cancer
Screening筛查
1.Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality withlow-dose computed tomographic screening. N Engl J Med.2011;365(5):395-409.
Staging分期
2.Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancerwith combined PET–CT. N Engl J Med.2009;361:32-39.
Surgeryfor NSCLC 非小细胞肺癌手术
3.Albain KS, RS Swann, VW Rusch, et al. Radiotherapy plus chemotherapy with orwithout surgical resection for stage III non-small-cell lung cancer: a phaseIII randomised controlled trial. Lancet. 2009;374:379-386.
AdjuvantTherapy 辅助治疗
4.Arriagada R, Bergman B, Dunant A, et al. The international adjuvant lung cancertrial collaborative group. Cisplatin-based adjuvant chemotherapy in patientswith completely resected non–small-cell lung cancer. N Engl J Med.2004;350(4):351-360.
5.Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs.observation in resected non–small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
6.Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non–small-celllung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991.
7.Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatinversus observation in patients with completely resected stage IB–IIIAnon-small-cell lung cancer (Adjuvant Navelbine International TrialistAssociation [ANITA]): a randomised controlled trial. Lancet Oncol.2006;7:719-727
8.Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatincompared with observation in stage IB non–small-cell lung cancer: CALGB 9633With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, andNorth Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov1;26(31):5043-5051.
9.Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized Phase III Studyof Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in StagesIB to IIIA Non–Small-Cell Lung Cancer. J Clin Oncol. Jan 10,2012:30;172-178.
10.Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant CisplatinEvaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul20;26(21):3552-3559.
Chemotherapyfor Metastatic Disease 转移性肺癌化疗
11.Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxelplus carboplatin versus vinorelbine plus cisplatin in the treatment of patientswith advanced non–small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol. 2001;19(13):3210-3218.
12.Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum,nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall celllung carcinoma: potential for decreased toxicity and combination withbiological therapy. Cancer. 2002;95(2):340-353.
13.Danson S, Middleton, MR, O’Byrne KJ, et al. Phase III trial of gemcitabine andcarboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin,vinblastine, and cisplatin in patients with advanced nonsmall cell lungcarcinoma.Cancer 2003;98:542-553.
14.Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapyregimens for advanced non–small-cell lung cancer. N Engl J Med.2002;346:92-98.
15.Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phaseIII study of docetaxel plus platinum combinations versus vinorelbine pluscisplatin for advanced non–small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-3024.
16.Hanna N, Shepherd F, Fossella FV, et al. Randomized phase III trial ofpemetrexed versus docetaxel in patients with non–small-cell lung cancerpreviously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597
Chemotherapyfor Metastatic Disease 转移性肺癌化疗
17.Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or withbevacizumab for non–small-cell lung cancer. N Engl J Med.2006;355:2542-2550.
18.NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportivecare improves survival in advanced non–small-cell lung cancer: a systematicreview and meta-analysis of individual patient data from 16 randomizedcontrolled trials. J Clin Oncol. 2008;17:7162.
19.Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparingcisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naivepatients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
20.Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy inpatients with advanced non-small-cell lung cancer (FLEX): an open-labelrandomised phase III trial. Lancet. 2009;373:1525-1531.
21.Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus bestsupportive care versus placebo plus best supportive care for non-small-celllung cancer: a randomised, double-blind, phase 3 study. Lancet.2009;374(9699):1432-1440.
22.Azzoli CG, Temin S, Aliff T, et al. 2011 Focused Update of 2009 AmericanSociety of Clinical Oncology Clinical Practice Guideline Update on Chemotherapyfor Stage IV Non–Small-Cell Lung Cancer. J Clin Oncol. 2011;29:1-8.
23.Temel JS, Greer JA, Muzikansky A, et al. Early Palliative Care for Patientswith Metastatic Non–Small-Cell Lung Cancer. N Engl J Med. 2010 Aug 19;363(8):733-42.
Chemo-RT放化疗
24.Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide,and chest radiotherapy in pathologic stage IIIB non–small-cell lung cancer: ASouthwest Oncology Group Phase II Study, SWOG 9019. J ClinOncol. 2002;20(16):3454-3460.
25.Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens ofpaclitaxel and carboplatin for locally advanced non–small-cell lung cancer: arandomized phase II locally advanced multi-modality protocol. JClin Oncol. 2005;55:405.
EpidermalGrowth Factor Receptor 表皮生长因子受体
26.Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treatednon–small-cell lung cancer. NEngl J Med. 2005;353:123-132.
27.Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer—— molecular andclinical predictors of outcome. NEngl J Med. 2005;353:133-144.
28.Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel inpulmonary adenocarcinoma. NEngl J Med. 2009;361:947-957.
29.Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients withadvanced non–small-cell lung cancer harboring epidermal growth factor receptormutations without indication for chemotherapy. JClin Oncol. 2009;27(9):1394-1401.
30.Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-linetreatment for patients with advanced EGFR mutation-positive non-small-cell lungcancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3study. LancetOncol. 2011;12(8):735-742.
31.Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT)in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermalgrowth factor receptor (EGFR) mutations: Interim results of the EuropeanErlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 29: 2011 (suppl; abstr 7503).
ALKInhibitors ALK抑制剂
32.Kwak EL, Bang Y-J, Camidge R, et al. Anaplastic lymphoma kinase inhibition innon–small-cell lung cancer. NEngl J Med. 2010;363:1693-1703.
Small Cell LungCancer
Chemotherapy化疗
33.Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen issuperior to cyclophosphamide, epirubicin, and vincristine regimen in small-celllung cancer: Results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol.2002 Dec 15;20(24):4665-4672.
34.Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared withetoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan10;346(2):85-91.
35.O'Brien MER, Ciuleanu T-E, Tsekov H, et al. Phase III trial comparingsupportive care alone with supportive care with oral topotecan in patients withrelapsed small-cell lung cancer. J Clin Oncol. 2006 Dec1;24(34):5441-5447.
ThoracicRadiation 胸部放疗
36.Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracicradiotherapy in limited small-cell lung cancer treated concurrently withcisplatin and etoposide. N Engl J Med. 1999 Jan28;340(4):265-271.
37.Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versussequential thoracic radiotherapy in combination with cisplatin and etoposidefor limited-stage small-cell lung cancer: results of the Japan ClinicalOncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-3060.
CranialRadiation 头颅放射
38.Aupérin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation forpatients with small-cell lung cancer in complete remission. ProphylacticCranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476-484.
39.Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation inextensive small-cell lung cancer. N Engl J Med. 2007 Aug16;357(7):664-672.
责任编辑：Lilith
苏公网安备32059002004080号
